CAJ | 학술논문

目的对比培关曲塞治疗与单纯对症支持治疗对进展恶性胸膜间皮瘤患者生存时间、疾病无进展生存期、药物敏感性、药物安全性的差异.方法选择治疗后复发的恶性胸膜间皮瘤患者26例,随机分为两组,治疗组11例,采用培美曲塞500 mg/m2,第1天,21 d为1个周期；对照组15例,采用单纯对症支持治疗.结果两种方案中位生存时间比较差异无统计学意义(治疗组8.1个月,对照组7.6个月；P=:0.775)；中位疾病无进展生存期分别为3.2个月和1.7个月(P＜0.05)；部分缓解率分别为18.2％和0％,疾病控制率为63.6％和13.3％.治疗组约7％患者出现Ⅲ～Ⅳ度血液毒性,化疗可耐受.结论培美曲塞单药在进展的恶性胸膜间皮瘤患者中显示出明显疗效.
목적 대비배관곡새치료여단순대증지지치료대진전악성흉막간피류환자생존시간、질병무진전생존기、약물민감성、약물안전성적차이.방법 선택치료후복발적악성흉막간피류환자26례,수궤분위량조,치료조11례,채용배미곡새500 mg/m2,제1천,21 d위1개주기；대조조15례,채용단순대증지지치료.결과 량충방안중위생존시간비교차이무통계학의의(치료조8.1개월,대조조7.6개월；P=:0.775)；중위질병무진전생존기분별위3.2개월화1.7개월(P＜0.05)；부분완해솔분별위18.2％화0％,질병공제솔위63.6％화13.3％.치료조약7％환자출현Ⅲ～Ⅳ도혈액독성,화료가내수.결론 배미곡새단약재진전적악성흉막간피류환자중현시출명현료효.
Objective To compare the difference of patients' survival time,disease progressionfree survival,drug susceptibility,drug safety between pemetrexed and single symptomatic supportive treatment in patients with advanced malignant pleural mesothelioma.Methods Twenty patients with relapsing malignant pleural mesothelioma were randomly divided into two groups,11 cases were treated with pemetrexed 500 mg/m2 was administered to patients on day 1 cycle of a 3-weeks,15 cases were treated only with single symptomatic supportive treatment.Results There was no significantly difference in median survival time between treatment group and control group(8.land 7.6 months ; P =0.775).Median progression-free survival time was respectively 3.2 months and 1.7 months (P ＜ 0.005).Partial response rate was 18.2％ and 0％ and the disease control rate was 63.6％ and 13.3％.7％ patients had modest grade 3 and 4 hematologic toxicities,the chemotherapy was well tolerated.Conclusions The effect of pemetrexed on patients with advanced malignant pleural mosethelioma is good.